User: Guest  Login
Document type:
journal article 
Author(s):
Agnelli, G; Gallus, A; Goldhaber, SZ; Haas, S; Huisman, MV; Hull, RD; Kakkar, AK; Misselwitz, F; Schellong, S 
Title:
Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study. 
Abstract:
BACKGROUND: An effective and safe oral anticoagulant that needs no monitoring for dose adjustment is urgently needed for the treatment of diseases that require long-term anticoagulation. Rivaroxaban (BAY 59-7939) is an oral direct factor Xa inhibitor currently under clinical development. METHODS AND RESULTS: This randomized, parallel-group phase II trial in patients with proximal deep-vein thrombosis explored the efficacy and safety of rivaroxaban 10, 20, or 30 mg BID or 40 mg once daily compare...    »
 
Journal title abbreviation:
Circulation 
Year:
2007 
Journal volume:
116 
Journal issue:
Pages contribution:
180-7 
Language:
eng 
Print-ISSN:
0009-7322 
TUM Institution:
r experimentelle Onkologie und Therapieforschung